Rani Therapeutics Holdings

Rani Therapeutics Holdings

Biotechnology
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

$92.2M

Market Cap • 10/9/2026

2021

(5 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,4

P/S

19,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,3

EPS

—

Market Cap

Market Cap

92,2M

EV

51,1M

EV/Revenue

10,5

EV/EBITDA

-1,6

EV/EBIT

-1,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-81,4%

Total Yield

-81,4%

Payout

0%

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

375,4%

Capex/Revenue

1%

Capex/D&A

6,5%

Capex/OCF

-0,2%

SBC/OCF

—

% PPE

6,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

10%

CAGR Op. Income 5Y

12,6%

CAGR Net Income 5Y

11,1%

CAGR OCF 5Y

5,3%

Leverage

N.D./EBITDA

1,5

Debt/Equity

0%

Current Ratio

5,3

Quick Ratio

5,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium